Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
22 Mar 2022 //
REUTERS
Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia
01 Mar 2021 //
PRNASIA
Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal
01 Mar 2021 //
PHARMAFILE